Literature DB >> 21723900

Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.

Muhammad Suleman1, Sandra Galea, Françoise Gavard, Nathalie Merillon, Bernard Klonjkowski, Eric Tartour, Jennifer Richardson.   

Abstract

Different subsets of dendritic cells (DC) elicit qualitatively different immune responses. In mice, two lymphoid tissue-resident subsets, CD8α(+) and CD8α(-), have been implicated in the induction of T helper 1 (Th1) or Th2 responses, respectively. Moreover, CD8α(+) DC appear to play a major role in priming CD8(+) T lymphocyte responses to viral antigens in the course of diverse viral infections. These considerations have been less extensively explored for vaccine vectors derived from viruses. Despite inefficient ex vivo transduction of DC, vectored vaccines derived from human adenoviruses of serotype 5 (Ad5) elicit robust immune responses, predominantly of the Th1 orientation, in humans and mice. At present it is unknown whether Ad5 interacts with DC subsets in a differential manner, thereby influencing the quality of the elicited IR. To address this issue, successive steps (attachment, transgene expression, MHC class I antigen presentation and activation of antigen-specific T lymphocytes) involved in induction of immune responses by Ad5-based vectors have been examined in CD8α(+) and CD8α(-) murine DC subsets. Although in both ex vivo and in vivo experiments CD8α(+) and CD8α(-) DC subsets captured an Ad5-based vector to a similar extent, transgene expression and subsequent MHC class I display of a transgene-encoded antigen were more efficient in CD8α(+) DC. Moreover, following in vivo and ex vivo transduction with an Ad5-based vaccine, antigen-specific CD8(+) T lymphocytes were more efficiently activated by CD8α(+) DC than by CD8α(-) DC. Thus, superior antigen expression and MHC class I display in CD8α(+) DC may contribute to preferred priming of antigen-specific CD8(+) lymphocytes by Ad5-transduced CD8α(+) DC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723900     DOI: 10.1016/j.vaccine.2011.06.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

2.  Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.

Authors:  Gisselle N Medina; Nestor Montiel; Fayna Diaz-San Segundo; Diego Sturza; Elizabeth Ramirez-Medina; Marvin J Grubman; Teresa de los Santos
Journal:  Clin Vaccine Immunol       Date:  2015-11-25

Review 3.  The influence of delivery vectors on HIV vaccine efficacy.

Authors:  Beatrice O Ondondo
Journal:  Front Microbiol       Date:  2014-08-22       Impact factor: 5.640

Review 4.  Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens.

Authors:  Sam Afkhami; Yushi Yao; Zhou Xing
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-27       Impact factor: 6.698

5.  Firewalls Prevent Systemic Dissemination of Vectors Derived from Human Adenovirus Type 5 and Suppress Production of Transgene-Encoded Antigen in a Murine Model of Oral Vaccination.

Authors:  Julien Revaud; Yves Unterfinger; Nicolas Rol; Muhammad Suleman; Julia Shaw; Sandra Galea; Françoise Gavard; Sandrine A Lacour; Muriel Coulpier; Nicolas Versillé; Menzo Havenga; Bernard Klonjkowski; Gina Zanella; Stéphane Biacchesi; Nathalie Cordonnier; Blaise Corthésy; Juliette Ben Arous; Jennifer P Richardson
Journal:  Front Cell Infect Microbiol       Date:  2018-01-25       Impact factor: 5.293

6.  Recall T cell responses to bluetongue virus produce a narrowing of the T cell repertoire.

Authors:  José-Manuel Rojas; Teresa Rodríguez-Calvo; Noemí Sevilla
Journal:  Vet Res       Date:  2017-06-29       Impact factor: 3.683

7.  Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexes.

Authors:  Ramona F Kratzer; Sigrid Espenlaub; Andrea Hoffmeister; Matthias W Kron; Florian Kreppel
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

8.  Immunogenicity of targeted lentivectors.

Authors:  Cleo Goyvaerts; De Groeve Kurt; Sandra Van Lint; Carlo Heirman; Jo A Van Ginderachter; Patrick De Baetselier; Geert Raes; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2014-02-15

9.  Vaccination with recombinant adenovirus expressing peste des petits ruminants virus-F or -H proteins elicits T cell responses to epitopes that arises during PPRV infection.

Authors:  José Manuel Rojas; Miguel Avia; Elena Pascual; Noemí Sevilla; Verónica Martín
Journal:  Vet Res       Date:  2017-11-21       Impact factor: 3.683

10.  Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Authors:  Rebecca K McLean; Alexandra J Spencer; Tobias J Tuthill; Teresa Lambe; Simon P Graham; Sandra Belij-Rammerstorfer; Daniel Wright; Marta Ulaszewska; Jane C Edwards; Jack W P Hayes; Veronica Martini; Nazia Thakur; Carina Conceicao; Isabelle Dietrich; Holly Shelton; Ryan Waters; Anna Ludi; Ginette Wilsden; Clare Browning; Dagmara Bialy; Sushant Bhat; Phoebe Stevenson-Leggett; Philippa Hollinghurst; Ciaran Gilbride; David Pulido; Katy Moffat; Hannah Sharpe; Elizabeth Allen; Valerie Mioulet; Chris Chiu; Joseph Newman; Amin S Asfor; Alison Burman; Sylvia Crossley; Jiandong Huo; Raymond J Owens; Miles Carroll; John A Hammond; Elma Tchilian; Dalan Bailey; Bryan Charleston; Sarah C Gilbert
Journal:  NPJ Vaccines       Date:  2020-07-27       Impact factor: 7.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.